ACE Inhibitor Selection for Heart Failure and Diabetes

Guideline-Based Approach to Selection

• The European Heart Journal guidelines list both lisinopril and ramipril as acceptable ACE inhibitors for heart failure, with established dosing: lisinopril 5-20 mg daily and ramipril 2.5-5 mg twice daily as maintenance doses 1
• The American Diabetes Association recommends ACE inhibitors or ARBs as the preferred treatment strategy for hypertension management in diabetes, particularly with albuminuria or coronary artery disease 2, 3, 4

Current Guideline Recommendations

• For patients with diabetes and stage B heart failure, ACE inhibitors/ARBs plus beta-blockers are recommended 2, 3, 4
• The class effect for ACE inhibitors in preventing heart failure progression was established in the SOLVD and SAVE studies 2, 3, 4

Practical Algorithm for Selection

• If primary indication is symptomatic heart failure, choose lisinopril with goal of titrating to 20 mg daily, or alternative ramipril 2.5-5 mg twice daily 1
• If primary indication is diabetes with high cardiovascular risk, choose ramipril 2.5-10 mg daily 4

Critical Monitoring Parameters

• Check serum creatinine and potassium within 2-4 weeks of initiation or dose increase, and accept up to 10-20% increase in serum creatinine as expected pharmacodynamic effect 5, 1
• Start with low doses in patients with baseline renal impairment, such as lisinopril 2.5 mg daily or ramipril 1.25-2.5 mg daily 1, 5